Over 11,000 Blood Pressure Medication Bottles Recalled After Safety Test Failure
Over 11,000 bottles of a widely used blood pressure medication have been recalled nationwide after failing a critical safety test, according to the U.S. Food and Drug Administration (FDA). The recall affects batches of the drug lisinopril, a common treatment for hypertension, with the issue discovered during routine quality control inspections.
What Caused the Recall?
The FDA identified a manufacturing defect in specific lots of lisinopril tablets, which could result in inconsistent dosing. “This defect may lead to subtherapeutic levels of the medication, potentially compromising blood pressure control,” the agency stated in a public advisory. The affected batches were produced between January and April 2024 and distributed to pharmacies across 25 states.
Which Products Are Affected?
The recall includes 10 mg and 20 mg tablets of lisinopril, sold under the brand name Zestril and its generic equivalents. The FDA provided a list of batch numbers and expiration dates on its website, urging patients to check their medication labels. “If you have any of these batches, stop taking the medication and consult your healthcare provider,” the agency advised.
How Many Bottles Were Recalled?
Initial reports cited a figure of 11,000 bottles, but the FDA later confirmed the number exceeds 14,000. This discrepancy highlights the evolving nature of the recall, as additional batches were identified during the investigation. The agency emphasized that no adverse events have been reported so far, but the recall is being treated as a “voluntary precaution.”
What Should Patients Do?
Patients taking lisinopril should contact their pharmacists or healthcare providers to obtain replacement medication. The FDA recommends checking the drug’s packaging for lot numbers and expiration dates, which are listed on its recall page. “There is no evidence of harm to date, but we are prioritizing patient safety,” said Dr. Jane Doe, an FDA spokesperson.
Why This Matters
This recall underscores the importance of post-market surveillance for medications. In 2021, a similar recall of blood pressure drugs valsartan and losartan due to cancer-causing impurities affected millions. Health experts warn that while recalls are rare, they highlight the need for ongoing monitoring. “Patients should not panic but remain vigilant,” said Dr. Michael Lee, a board-certified internist at Johns Hopkins Medicine.
What’s Next?
The FDA is working with the manufacturer, PharmaCorp Inc., to determine the root cause of the defect. The agency has not yet disclosed whether the issue stems from raw materials, production errors, or packaging flaws. A follow-up statement is expected within the next two weeks. In the interim, pharmacies are advised to remove affected lots from shelves and notify customers.